Nevertheless, these treatments are also related to acute ILD exacerbations, with incidence ranging from 4% for gefitinib to 2.14% with anti-ALK targeted treatments, especially in Japanese populations, whereas moderate and severe Grade 5 pneumonitis is significantly less prevalent in non-Asian populations [75,76,77,78]. Here, ALK is linked to interstitial lung disease.